Efficacy of High-Dose Palliative Radiotherapy For Localised, Castration-Resistant Prostate Cancer

Abstract

Aims: There are limited outcome data after radiotherapy treatment for clinically localised, castration-resistant prostate cancer. We report our single institution experience on patient outcomes in this group using high-dose palliative radiotherapy (HDPRT). Materials and methods: A retrospective review of patient hospital records was conducted in prostate cancer patients treated with palliative intent radiotherapy and restricted to those who had castration-resistant disease, no evidence of regional or distant disease and who received a local radiotherapy dose equivalent to 40Gy or greater. Results: Fifty-one patients met the study criteria, 88% of these had high-risk disease at initial diagno..